Share this article on:

Efficacy of Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine Based on Breastfeeding Frequency

Goveia, Michelle G. MD, MPH; DiNubile, Mark J. MD; Dallas, Michael J. PhD; Heaton, Penny M. MD; Kuter, Barbara J. PhD, MPHfor the REST Study Team

The Pediatric Infectious Disease Journal: July 2008 - Volume 27 - Issue 7 - p 656-658
doi: 10.1097/INF.0b013e318168d29e
Brief Reports

The efficacy of a live, oral, pentavalent rotavirus vaccine against G1-4 rotavirus gastroenteritis (RVGE) was retrospectively assessed based on breastfeeding frequency among 5098 infants in a placebo-controlled trial. The efficacy against any RVGE severity for infants never breastfed, sometimes breastfed, or exclusively breastfed was 68.3%, 82.2%, and 68.0%, respectively. The efficacy against severe RVGE was 100%, 95.4%, and 100%, respectively. Breastfeeding did not seem to adversely impact the efficacy of pentavalent rotavirus vaccine.

From Merck & Co., Inc., West Point, PA.

Accepted for publication January 14, 2008.

This study was sponsored and supported by Merck & Co., Inc.

Address for correspondence: Barbara J. Kuter, PhD, MPH, Merck & Co., Inc, PO Box 4, West Point, PA 19486. E-mail:

© 2008 Lippincott Williams & Wilkins, Inc.